Market Overview:
The global plasma derived medicine market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for plasma-derived medicines, and technological advancements in the field of plasma-derived medicines. Based on type, the global plasma derived medicine market is segmented into albumin, coagulation factor VIII & IX, immunoglobulin G (IgG), and other products. The albumin segment is expected to account for the largest share of the global market in 2018. This can be attributed to its high usage in various applications such as trauma care and surgery patients. Based on application, hospitals are expected to account for the largest share of the global market in 2018.
Product Definition:
Plasma derived medicine is a treatment that uses blood plasma to help improve a person's health. Plasma derived medicines can be used to treat a variety of medical conditions, including bleeding disorders, immune system deficiencies, and neurological disorders.
Albumin:
Albumin is a protein that is found in the human body. It helps maintain the fluid balance and helps remove waste products from the blood. The normal level of albumin in an adult human being is 40-60 grams per liter of plasma. Plasma derived medicines are used for various purposes such as to treat hypoalbuminemia, hyperalbunemia, liver disease and kidney disease among others.
Coagulation Factor:
Coagulation factor is a protein that promotes blood clotting. It is produced by the liver and kidneys in response to injury or stress to the body. The normal level of Coagulation Factor in humans is 1.5-10 gm per liter of plasma depending upon age, diet, and other factors.
Application Insights:
Based on the application, the market is segmented into hospitals, clinics and other. The other applications include research institutes and industrial manufacturing facilities. Hospitals are expected to be at the forefront of adoption owing to their ability to offer personalized treatments with a higher success rate than clinics or other medical facilities.
The clinics segment is anticipated to witness lucrative growth over the forecast period due largely in part to increasing awareness about Plasma Protein Therapeutics (PHT) which includes its usage for treating diseases such as hemophilia, protein C deficiency and others. PHT replacement therapy has been found more effective than regular medication in many cases resulting in increased adoption of plasma derived medicine across clinical settings over hospitals or any other type of healthcare facility.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period owing to high R&D investments and increasing adoption of plasma-derived therapies. In addition, growing healthcare awareness levels and supportive reimbursement policies are also contributing towards regional growth.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure levels, improving infrastructure facilities in rural areas as well as cities, and an increase in patient pool due to aging demographics especially in Japan & China. Moreover, government initiatives for spreading awareness about plasma-derived medicines are also expected favorably impact regional demand during the same period (2018 - 2030). ‘’ ‘’ ‘’ â‘œ)© 2018 Derma Sciences Inc.
Growth Factors:
- Increasing incidence of chronic diseases: The prevalence of chronic diseases is increasing at an alarming rate across the globe. This is primarily because of the changing lifestyle and dietary habits of people. Plasma derived medicines are used for the treatment of a wide range of chronic diseases such as hemophilia, Gaucher’s disease, and thalassemia. Thus, the demand for plasma derived medicines is expected to rise in the coming years.
- Technological advancements: The technology used for manufacturing plasma derived medicines has been evolving rapidly in recent years. This has led to an increase in their efficacy and safety profile. Moreover, new applications for these drugs are being discovered on a regular basis which is likely to fuel market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Plasma Derived Medicine Market Research Report
By Type
Albumin, Coagulation Factor, Immunoglobulin, Others
By Application
Hospitals, Clinics, Other
By Companies
Grifols, SK Plasma, Fusion Health Care, Biotest AG, GC Pharma, Baxter International, LFB, Octapharma AG, CSL Limited, BPL, China Biologic Products, Kedrion Biopharma, RAAS, Tiantan Bio, Hualan Biological Engineering, BOYA Bio-Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
200
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Plasma Derived Medicine Market Report Segments:
The global Plasma Derived Medicine market is segmented on the basis of:
Types
Albumin, Coagulation Factor, Immunoglobulin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Grifols
- SK Plasma
- Fusion Health Care
- Biotest AG
- GC Pharma
- Baxter International
- LFB
- Octapharma AG
- CSL Limited
- BPL
- China Biologic Products
- Kedrion Biopharma
- RAAS
- Tiantan Bio
- Hualan Biological Engineering
- BOYA Bio-Pharmaceutical
Highlights of The Plasma Derived Medicine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Albumin
- Coagulation Factor
- Immunoglobulin
- Others
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Plasma Derived Medicine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Plasma derived medicine is a type of medication that is made from the blood plasma (the liquid portion of blood) of healthy people. Plasma derived medicines are often used to treat conditions such as cancer, autoimmune diseases, and rare genetic disorders.
Some of the key players operating in the plasma derived medicine market are Grifols, SK Plasma, Fusion Health Care, Biotest AG, GC Pharma, Baxter International, LFB, Octapharma AG, CSL Limited, BPL, China Biologic Products, Kedrion Biopharma, RAAS, Tiantan Bio, Hualan Biological Engineering, BOYA Bio-Pharmaceutical.
The plasma derived medicine market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Plasma Derived Medicine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Plasma Derived Medicine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Plasma Derived Medicine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Plasma Derived Medicine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Plasma Derived Medicine Market Size & Forecast, 2018-2028
4.5.1 Plasma Derived Medicine Market Size and Y-o-Y Growth
4.5.2 Plasma Derived Medicine Market Absolute $ Opportunity
Chapter 5 Global Plasma Derived Medicine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Plasma Derived Medicine Market Size Forecast by Type
5.2.1 Albumin
5.2.2 Coagulation Factor
5.2.3 Immunoglobulin
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Plasma Derived Medicine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Plasma Derived Medicine Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Plasma Derived Medicine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Plasma Derived Medicine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Plasma Derived Medicine Analysis and Forecast
9.1 Introduction
9.2 North America Plasma Derived Medicine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Plasma Derived Medicine Market Size Forecast by Type
9.6.1 Albumin
9.6.2 Coagulation Factor
9.6.3 Immunoglobulin
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Plasma Derived Medicine Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Plasma Derived Medicine Analysis and Forecast
10.1 Introduction
10.2 Europe Plasma Derived Medicine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Plasma Derived Medicine Market Size Forecast by Type
10.6.1 Albumin
10.6.2 Coagulation Factor
10.6.3 Immunoglobulin
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Plasma Derived Medicine Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Plasma Derived Medicine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Plasma Derived Medicine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Plasma Derived Medicine Market Size Forecast by Type
11.6.1 Albumin
11.6.2 Coagulation Factor
11.6.3 Immunoglobulin
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Plasma Derived Medicine Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Plasma Derived Medicine Analysis and Forecast
12.1 Introduction
12.2 Latin America Plasma Derived Medicine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Plasma Derived Medicine Market Size Forecast by Type
12.6.1 Albumin
12.6.2 Coagulation Factor
12.6.3 Immunoglobulin
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Plasma Derived Medicine Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Plasma Derived Medicine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Plasma Derived Medicine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Plasma Derived Medicine Market Size Forecast by Type
13.6.1 Albumin
13.6.2 Coagulation Factor
13.6.3 Immunoglobulin
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Plasma Derived Medicine Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Plasma Derived Medicine Market: Competitive Dashboard
14.2 Global Plasma Derived Medicine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Grifols
14.3.2 SK Plasma
14.3.3 Fusion Health Care
14.3.4 Biotest AG
14.3.5 GC Pharma
14.3.6 Baxter International
14.3.7 LFB
14.3.8 Octapharma AG
14.3.9 CSL Limited
14.3.10 BPL
14.3.11 China Biologic Products
14.3.12 Kedrion Biopharma
14.3.13 RAAS
14.3.14 Tiantan Bio
14.3.15 Hualan Biological Engineering
14.3.16 BOYA Bio-Pharmaceutical
